American Society of Hematology

Figure 3.

$Figure 3. Imatinib mesylate treatment results in T-cell accumulation in the G0/G1 phase of the cell cycle but does not inhibit T-cell activation. (A) Cell cycle distribution of unstimulated T cells and T cells stimulated with PHA, or the combination of PHA- and IL-2–stimulated T cells with and without imatinib mesylate. The cells were stained with propidium iodide 24 hours after initiation of experiment and analyzed by flow cytometry. ▪ represents the fraction of cells in G0/G1; ▦, the fraction in S phase; and □, the fraction in G2/M phase. Shown are mean values ± SD. (B) Untreated T cells (dashed line) and T cells activated with PHA (10 μg/mL) in imatinib mesylate absence (solid line) or presence (10 μM; shaded area) were analyzed for expression of CD25 or CD69 24 hours after initiation of culture.$

Imatinib mesylate treatment results in T-cell accumulation in the G₀/G₁ phase of the cell cycle but does not inhibit T-cell activation. (A) Cell cycle distribution of unstimulated T cells and T cells stimulated with PHA, or the combination of PHA- and IL-2–stimulated T cells with and without imatinib mesylate. The cells were stained with propidium iodide 24 hours after initiation of experiment and analyzed by flow cytometry. ▪ represents the fraction of cells in G₀/G₁; ▦, the fraction in S phase; and □, the fraction in G₂/M phase. Shown are mean values ± SD. (B) Untreated T cells (dashed line) and T cells activated with PHA (10 μg/mL) in imatinib mesylate absence (solid line) or presence (10 μM; shaded area) were analyzed for expression of CD25 or CD69 24 hours after initiation of culture.

This Feature Is Available To Subscribers Only